1. Li, Ming D, Lou, Xiang-Yang, Chen, Guobo, Ma, Jennie Z, Elston, Robert C. 2008. Gene-gene interactions among CHRNA4, CHRNB2, BDNF, and NTRK2 in nicotine dependence. In Biological psychiatry, 64, 951-7. doi:10.1016/j.biopsych.2008.04.026. https://pubmed.ncbi.nlm.nih.gov/18534558/
2. Qin, Cheng, Li, Tianhao, Wang, Yuanyang, Zhao, Yutong, Wang, Weibin. 2022. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. In Cancer cell international, 22, 340. doi:10.1186/s12935-022-02768-8. https://pubmed.ncbi.nlm.nih.gov/36344976/
3. Hoft, N R, Stitzel, J A, Hutchison, K E, Ehringer, M A. 2010. CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences. In Genes, brain, and behavior, 10, 176-85. doi:10.1111/j.1601-183X.2010.00650.x. https://pubmed.ncbi.nlm.nih.gov/20854418/
4. Cadieux-Dion, Maxime, Meneghini, Simone, Villa, Chiara, Becchetti, Andrea, Nguyen, Dang Khoa. 2020. Variants in CHRNB2 and CHRNA4 Identified in Patients with Insular Epilepsy. In The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 47, 800-809. doi:10.1017/cjn.2020.126. https://pubmed.ncbi.nlm.nih.gov/32536355/
5. Kanda, Mitsuro, Shimizu, Dai, Nakamura, Shunsuke, Katsuno, Masahisa, Kodera, Yasuhiro. 2021. Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. In Oncogene, 40, 5495-5504. doi:10.1038/s41388-021-01945-9. https://pubmed.ncbi.nlm.nih.gov/34331011/